Gut microbiota interact with the brain through systemic chronic inflammation: implications on neuroinflammation, neurodegeneration, and aging

Y Mou, Y Du, L Zhou, J Yue, X Hu, Y Liu… - Frontiers in …, 2022 - frontiersin.org
It has been noticed in recent years that the unfavorable effects of the gut microbiota could
exhaust host vigor and life, yet knowledge and theory are just beginning to be established …

[HTML][HTML] BCG-induced cross-protection and development of trained immunity: implication for vaccine design

C Covián, A Fernández-Fierro, A Retamal-Díaz… - Frontiers in …, 2019 - frontiersin.org
The Bacillus Calmette-Guérin (BCG) is a live attenuated tuberculosis vaccine that has the
ability to induce non-specific cross-protection against pathogens that might be unrelated to …

The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody

R Höftberger, Y Guo, EP Flanagan… - Acta …, 2020 - Springer
We sought to define the pathological features of myelin oligodendrocyte glycoprotein (MOG)
antibody associated disorders (MOGAD) in an archival autopsy/biopsy cohort. We …

[HTML][HTML] Comorbidity in multiple sclerosis

M Magyari, PS Sorensen - Frontiers in Neurology, 2020 - frontiersin.org
Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing
interest in the recent years. A comorbidity is defined as any additional disease that coexists …

Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis

C Barro, BC Healy, Y Liu, S Saxena… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Neurodegeneration and astrocytic activation are pathologic
hallmarks of progressive multiple sclerosis (MS) and can be quantified by serum …

The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

PS Sorensen, F Sellebjerg, HP Hartung, X Montalban… - Brain, 2020 - academic.oup.com
In the past decade, changes have occurred in the spectrum of multiple sclerosis courses.
The natural history of multiple sclerosis appears milder from the first sign of demyelinating …

Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion

M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - Springer
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

M Filippi, R Danesi, T Derfuss, M Duddy, P Gallo… - Journal of …, 2022 - Springer
Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best
strategy to delay irreversible neurological damage and progression of multiple sclerosis …

Role of vitamin D in preventing and treating selected extraskeletal diseases—an umbrella review

F Maretzke, A Bechthold, S Egert, JB Ernst… - Nutrients, 2020 - mdpi.com
Evidence is accumulating that vitamin D may have beneficial effects on respiratory tract,
autoimmune, neuro-degenerative, and mental diseases. The present umbrella review of …

[HTML][HTML] Immunosenescence in multiple sclerosis: the identification of new therapeutic targets

M Dema, H Eixarch, LM Villar, X Montalban… - Autoimmunity …, 2021 - Elsevier
The number of elderly multiple sclerosis (MS) patients is growing, mainly due to the increase
in the life expectancy of the general population and the availability of effective disease …